血脂康胶囊与普伐他汀治疗高胆固醇血症的成本-效果分析

目的：探讨血脂康和普伐他汀治疗高胆固醇血症的经济效果。方法：将79例高胆固醇血症患随机分为两组(血脂康组37例，普伐他汀组42例)，用药物经济学方法进行成本-效果分析。结果：总胆固醇(TC)每下降1mmol／L，血脂康和普伐他汀的费用分别是473．02元、642．12元：甘油三酯(TG)每下降1mmol／L，费用分别是2003．38元、6788．21元；低密度脂蛋白胆固醇(LDL—c)每下降1mmol／L，费用分剐是490．03元、693．68元；在血脂康疗效的基础上增加一个效果单位，费用分别是100．00元、338．84元。相比而言，血脂康成本-效果低于普伐他汀。结论：药物经济学研究可以弥补临床药物疗效观察研究的不足，在指导合理用药、减轻患经济负担、提高社会经济效益和指导萨药开发方面具有重要作用。

Application of Cost-effectiveness Analysis in Xuezhikang and Pravastatin for the Treatment Hypercholesterolemia

Objective:To evaluate the economic effectiveness in the treatment of hypercholesterolemia by Xuezhikang and Pravastatin differently. Methods:79 patients with hypercholesterolemia were randomly divided into two groups.Using pharmacoeconomical cost-effectiveness analysis, Xuezhikang and pravastatin were compared for the treatment of hypercholesterolemia. Results:The cost of Xuezhikang and pravastatin lowering per 1 mmol/L TC were RMB 473.02 yuans and 642.12 yuans , lowering per 1 mmol/L TG were RMB 2 003.38 yuans and 6 788.21 yuans, lowering per 1 mmol/L LDL-c were RMB 490.3 yuans and 693.68 yuans. Xuezhikang was better than pravastatin in lasting treatment for hypercholesterolemia. Conclusion:The results show that pharmacoeconomics is very important in guiding rational drug use and increasing economic effectiveness.